Navigation Links
AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 8, 2007 - AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced Phase III data on the efficacy, safety and improvements in patient-centered outcomes in patients with diabetic peripheral neuropathic (DPN) pain treated with the investigational drug Zenvia(TM) (dextromethorphan / quinidine) will be presented in two scientific posters at the Second International Congress on Neuropathic Pain, being held in Berlin, Germany on June 7 to 10, 2007.

Both posters will be presented at Poster Session 1: Clinical - Pharmacotherapy on Friday, June 8, 2007, between 1:30 p.m. and 3:30 p.m. Central European time (CET).

"This scientific congress serves as a showcase for new developments in pain treatment. We are pleased that these data have been recognized as important by the congress organizers and accepted for presentation," said Randall Kaye, MD, Chief Medical Officer of AVANIR Pharmaceuticals.

The accepted posters are:

-- Poster number 1497: EFFICACY AND SAFETY OF DEXTROMETHORPHAN/QUINIDINE IN TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY: RESULTS OF A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

-- Poster number 1498: IMPROVED PATIENT-CENTERED OUTCOMES WITH DEXTROMETHORPHAN/QUINIDINE VS PLACEBO IN A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL INVESTIGATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY

On April 18, 2007 AVANIR Pharmaceuticals announced positive top-line results from a Phase III study of Zenvia in patients with DPN pain. In the trial, two doses of Zenvia, 45/30 mg DMQ dosed twice daily (DMQ 45) and 30/30 mg DMQ dosed twice daily (DMQ 30), were compared to placebo based on daily patient diary entries for the Pain Rating Scale, which was the primary endpoint as defined in the Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). Both Zenvia treatment groups had lower pain rating
'"/>




Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
(Date:12/19/2014)... , Dec. 18, 2014 Since last ... the site now known as the leading online black ... seen explosive growth in its offering of drugs and ... Alliance show the takedowns did succeed in lowering the ... last review of the markets in August. But some ...
(Date:12/17/2014)... Los beneficios y ganancias están ... de gasto en investigación y desarrollo   ... de septiembre de 2014) ZEISS aumentó sus ingresos en ... (año anterior: 4.190 millones de euros) a pesar de ... crecieron un 14 por ciento, a 360 millones de ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3ZEISS confirma su posición en un entorno difícil 2
(Date:12/19/2014)... Dallas, TX (PRWEB) December 19, 2014 ... current state of the global Gliquidone industry with a ... statistics on the market status of the Gliquidone manufacturers ... for companies and individuals interested in the industry. , ... industry including its definition, applications and manufacturing technology. Then, ...
(Date:12/19/2014)... (HealthDay News) -- The tragic death from "rat-bite fever" of ... the pet rodents, according to a report from the U.S. ... a rare but potentially fatal illness that should be considered ... a history of rodent exposure is reported," said a team ... Service. The case outlined in the report occurred in ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 ... for at least 20 seconds you may be at risk ... one leg may indicate that small strokes or tiny bleeds ... strokes is high, the investigators reported online Dec. 18 in ... standing on one leg, as well as problems walking, should ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one ... rate variability (HRV), heart coherence and the physiology ... databases and algorithms to chipset manufacturers and consumer ... partners to offer its HRV solutions, tap into ... as its normative HRV databases and algorithms for ...
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
Breaking Medicine News(10 mins):Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... BRUNSWICK, N.J. Researchers at Rutgers Ernest Mario School ... the widely used drugs Celebrex (celecoxib, a nonsteroidal anti-inflammatory ... the transition of early prostate cancer to its more ... is the second leading cause of cancer death in ...
... Cancer Center at Thomas Jefferson University in Philadelphia ... pressure medications might help prevent the spread of ... that one type of pressure-lowering drug called an ... and causes cell death. , In earlier work ...
... discovered evidence that a series of genetic mutations work ... often-fatal form of acute lymphoblastic leukemia (ALL). , These ... of a gene, IKZF1, whose protein, Ikaros, normally helps ... a lymphocyte. The researchers also found that loss of ...
... Patented OwnCode(R) Consumer Heart Rate Monitor Technology Now Available in ... ... 2008 Polar, the leader in,heart rate monitoring and fitness ... only available in,Polar heart rate monitors -- can now be ...
... Calif., April 14 HealthFusion, a,national ... recognized for,call center operation customer satisfaction ... Certified Call Center Program(SM). This distinction,acknowledges ... call center,operations to provide "An Outstanding ...
... Galien USA 2008 Announced for September 24, Nominations ... Nobel Laureate Walter,Gilbert, Ph.D., the Carl M. Loeb ... Biogen, has joined fellow Nobel Laureates on the,committee ... research. Prix Galien USA 2008,( http://www.prix-galien-usa.com ) will ...
Cached Medicine News:Health News:Celebrex-Lipitor combo may halt prostate cancer 2Health News:Celebrex-Lipitor combo may halt prostate cancer 3Health News:Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find 2Health News:St. Jude discovery offers new avenues to understanding an aggressive form of leukemia 2Health News:St. Jude discovery offers new avenues to understanding an aggressive form of leukemia 3Health News:Polar Introduces Cost-Effective Solution to Reduce Heart Rate Data Cross-Talk 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 3Health News:Prix Galien USA Welcomes Eighth Nobel Laureate to its Prestigious Award Committee 2Health News:Prix Galien USA Welcomes Eighth Nobel Laureate to its Prestigious Award Committee 3